Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEMESIS

Financiado

Cerrado

Neuroprotection in Multiple Sclerosis From Molecular Imaging to Screenable Mode...

Neuroprotection in Multiple Sclerosis From Molecular Imaging to Screenable Models "Multiple Sclerosis (MS) is an inflammatory CNS disease that affects more than 2.5 million individuals worldwide. Damage to axonal connections determines the functional deficits of MS patients. How axons are damaged in MS is only... ver más

30/11/2017

LMU MUENCHEN

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-11-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

LMU MUENCHEN

0.00€ | Lider

Proyectos interesantes

LinkFM

Medical Technol...

Applied Physics

219K€ Cerrado

MicroCONtACT

Medical Technol...

Applied Physics

2M€ Cerrado

AXOGLIA

Medical Technol...

Neurology

149K€ Cerrado

PID2019-109724RB-I00

Medical Technol...

Applied Physics

298K€ Cerrado

PGC2018-094307-B-I00

Medical Technol...

Applied Physics

303K€ Cerrado

IMAGINE

Medical Technol...

Applied Physics

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Multiple Sclerosis (MS) is an inflammatory CNS disease that affects more than 2.5 million individuals worldwide. Damage to axonal connections determines the functional deficits of MS patients. How axons are damaged in MS is only incompletely understood. Using in vivo multiphoton imaging we have discovered a novel axon loss process that underlies axonal damage in experimental and human neuroinflammatory lesions. We have termed this process Focal Axonal Degeneration (FAD). FAD is characterized by a sequence of morphologically defined stages that ultimately result in axonal fragmentation. Notably, intermediate stages of FAD can persist for several days in vivo and still recover spontaneously. In this proposal I want to explore the biological and medical significance of FAD by addressing its: 1. Functional Characteristics I want to analyze two key aspects of axonal function, the ability to transport cargoes and the ability to propagate action potentials, in experimental neuroinflammatory lesions to better understand the in vivo relation between structural and functional deficits during axon damage. 2. Molecular Mechanisms I want to deploy new molecular imaging approaches to directly monitor the redox potential, calcium and ATP levels of axons and their mitochondria in experimental neuroinflammatory lesions. This will allow us to reveal the key effector mechanisms of FAD and the sequence in which they are activated in vivo. 3.Therapeutic Opportunities I plan to make use of advances in automated imaging and microfluidics to develop new in vivo assays for high-throughput screening of therapeutic interventions. This will help us to identify novel strategies for limiting progression and improving recovery of axon damage. The proposed project should provide new insights into the functional and molecular underpinnings of axon damage in vivo, establish new tools and models to study it and guide the development of therapeutic strategies that can prevent or reverse it."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores